In a Phase 1/2a study of patients with breast carcinoma harboring an amplification of FGFR1, FGF3, FGF4, or FGF19, lucitanib resulted in a disease control rate (DCR) of 100%; 50% (6/12) of patients achieved PR and 50% (6/12) of patients had SD. Here, FGF19 is linked to breast carcinoma.